Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zeltia SA

Division of PharmaMar SA
www.zeltia.es

Latest From Zeltia SA

European Notebook: Rasi To Review EMA Plans; Spain’s Drug Spend Held Flat By Industry; Insurers Merge In Germany

Re-appointed EMA Executive Director Guido Rasi will outline his plans for the agency in early December; pact in Spain calls for the pharmaceutical industry to reimburse government for spending increases above GDP growth.

BioPharmaceutical Germany

Allergy Therapeutics To Enter U.S. Allergy Market With 2019 Launch

Launch of the first FDA-approved subcutaneous allergy vaccine may be four years away, but the European specialty company is starting to plan for commercialization and market growth.

BioPharmaceutical Europe

Endocyte Anticipating Positive CHMP Opinion On Ovarian Cancer Drug/Diagnostic Combo

Endocyte and Merck are preparing to launch a combo drug/diagnostic in folate receptor-positive platinum-resistant ovarian cancer, a condition with a very poor survival prognosis, later this year in the EU. Medical affairs staff are meeting with specialists to discuss how the diagnostic can target patients most likely to respond in pre-approval commercial efforts.

BioPharmaceutical United States

Deals Shaping The Medical Industry (01/2012)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Grupo Zeltia
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Spain
  • Parent & Subsidiaries
  • PharmaMar SA
  • Senior Management
  • J.M. Fernandez Sousa, Pres.
  • Contact Info
  • Zeltia SA
    Phone: (34) 914 444 500
    Plaza del Descubridor, Diego de Ordas 3
    planta 5
    Madrid, 28003
    Spain
Advertisement
Advertisement
UsernamePublicRestriction

Register